341036-37-1

Basic information

• Product Name: N-((2-chloro-5-nitrophenyl)carbamothioyl)benzamide
• Synonyms: N-((2-chloro-5-nitrophenyl)carbamothioyl)benzamide
• CAS NO: 341036-37-1
• Molecular Weight: 335.771
• Mol File: 341036-37-1.mol

Chemical Properties

• CAS DataBase Reference: N-((2-chloro-5-nitrophenyl)carbamothioyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((2-chloro-5-nitrophenyl)carbamothioyl)benzamide(341036-37-1)
• EPA Substance Registry System: N-((2-chloro-5-nitrophenyl)carbamothioyl)benzamide(341036-37-1)

Safety Data

• Hazardous Substances Data: 341036-37-1(Hazardous Substances Data)

Upstream product

• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 98-88-4 benzoyl chloride 
• 532-55-8 Benzoyl isothiocyanate 

Downstream Products

• 916051-86-0 (5Z)-2-[(5-amino-2-chlorophenyl)amino]-5-(6-quinolinylmethylidene)-1,3-thiazol-4(5H)-one 
• 73458-39-6 5-nitro-benzothiazol-2-ylamine 
• 341036-39-3 2-chloro-5-nitrophenylthiourea 

Relevant articles and documents

Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds

Two series of compounds carrying 3-amino-1,2,4-triazole scaffold were synthesized and evaluated for their anticancer activity against a panel of cancer cell lines using XTT assay. The 1,2,4-triazole synthesis was revisited for the first series of pyridyl derivatives. The biological results revealed the efficiency of the 3-amino-1,2,4-triazole core that could not be replaced and a clear beneficial effect of a 3-bromophenylamino moiety in position 3 of the triazole for both series (compounds 2.6 and 4.6) on several cell lines tested. Moreover, our results point out an antiangiogenic activity of these compounds. Overall, the 5-aryl-3-phenylamino-1,2,4-triazole structure has promising dual anticancer activity.

THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones.

Kinetics and mechanism of methanolysis and cyclization of 1-acyl-3-(2-halo-5-nitrophenyl)thioureas

The kinetics of methoxide ion-catalysed solvolysis of 1-acyl-3-(2-halo-5-nitrophenyl)thioureas and cyclization of fluoro derivatives were studied in methanol at 25 deg C. The cyclization involved the substitution of fluorine by sulphur anion of thiourea and proceeded in two steps. With the acetyl derivative, the first step is methanolysis and the second step is much slower cyclization of the 2-fluoro-5-nitrophenylthiourea anion formed to give 2-amino-5-nitro-1,3-benzothiazole. With the benzoyl derivative, the first step involves parallel methanolysis of the benzoyl group and cyclization to 2-benzoylamino-5-nitro-1,3-benzothiazole. At concentrations of sodium methoxide higher than ca. 0.01 mol l-1 the rates of solvolyses of all the acyl halothioureas decreased and at concentrations higher than ca. 0.01 mol l-1 the rates of solvolyses of all the acyl halothioureas decreased and at concentrations higher than ca. 0.4 mol l-1 there was an increase in the formation of other product(s) than the product of cyclization. After the addition of 18-crown-6, the side products were not formed and the cyclization of fluoro derivatives were considerably accelerated. The slowing of the solvolytic reaction and acceleration of the cyclization reaction are most probably due to the formation of dianions.